Departments of1Neurosurgery.
2Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota; and.
J Neurosurg. 2021 Jun 4;136(1):1-8. doi: 10.3171/2020.10.JNS203366. Print 2022 Jan 1.
The authors' goal was to use a multicenter, observational cohort study to determine whether supramarginal resection (SMR) of FLAIR-hyperintense tumor beyond the contrast-enhanced (CE) area influences the overall survival (OS) of patients with isocitrate dehydrogenase-wild-type (IDH-wt) glioblastoma after gross-total resection (GTR).
The medical records of 888 patients aged ≥ 18 years who underwent resection of GBM between January 2011 and December 2017 were reviewed. Volumetric measurements of the CE tumor and surrounding FLAIR-hyperintense tumor were performed, clinical variables were obtained, and associations with OS were analyzed.
In total, 101 patients with newly diagnosed IDH-wt GBM who underwent GTR of the CE tumor met the inclusion criteria. In multivariate analysis, age ≥ 65 years (HR 1.97; 95% CI 1.01-2.56; p < 0.001) and contact with the lateral ventricles (HR 1.59; 95% CI 1.13-1.78; p = 0.025) were associated with shorter OS, but preoperative Karnofsky Performance Status ≥ 70 (HR 0.47; 95% CI 0.27-0.89; p = 0.006), MGMT promotor methylation (HR 0.63; 95% CI 0.52-0.99; p = 0.044), and increased percentage of SMR (HR 0.99; 95% CI 0.98-0.99; p = 0.02) were associated with longer OS. Finally, 20% SMR was the minimum percentage associated with beneficial OS (HR 0.56; 95% CI 0.35-0.89; p = 0.01), but > 60% SMR had no significant influence (HR 0.74; 95% CI 0.45-1.21; p = 0.234).
SMR is associated with improved OS in patients with IDH-wt GBM who undergo GTR of CE tumor. At least 20% SMR of the CE tumor was associated with beneficial OS, but greater than 60% SMR had no significant influence on OS.
作者的目标是通过一项多中心观察性队列研究,确定在 GTR 后,是否对强化 MRI(CE)区域以外的 FLAIR 高信号肿瘤进行边缘性切除(SMR),是否会影响异柠檬酸脱氢酶野生型(IDH-wt)胶质母细胞瘤患者的总生存期(OS)。
回顾了 2011 年 1 月至 2017 年 12 月期间接受 GBM 切除术的 888 名年龄≥18 岁患者的病历。对 CE 肿瘤和周围 FLAIR 高信号肿瘤进行容积测量,获取临床变量,并分析与 OS 的相关性。
共有 101 例新诊断的 IDH-wt GBM 患者接受了 CE 肿瘤的 GTR,符合纳入标准。多变量分析显示,年龄≥65 岁(HR 1.97;95%CI 1.01-2.56;p<0.001)和与侧脑室接触(HR 1.59;95%CI 1.13-1.78;p=0.025)与较短的 OS 相关,但术前 Karnofsky 表现状态≥70(HR 0.47;95%CI 0.27-0.89;p=0.006)、MGMT 启动子甲基化(HR 0.63;95%CI 0.52-0.99;p=0.044)和 SMR 百分比增加(HR 0.99;95%CI 0.98-0.99;p=0.02)与较长的 OS 相关。最后,20%的 SMR 是与 OS 获益相关的最小百分比(HR 0.56;95%CI 0.35-0.89;p=0.01),但>60%的 SMR 无显著影响(HR 0.74;95%CI 0.45-1.21;p=0.234)。
在接受 CE 肿瘤 GTR 的 IDH-wt GBM 患者中,SMR 与改善 OS 相关。CE 肿瘤至少 20%的 SMR 与 OS 获益相关,但大于 60%的 SMR 对 OS 无显著影响。